BR112015029318A2 - marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável - Google Patents

marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável

Info

Publication number
BR112015029318A2
BR112015029318A2 BR112015029318A BR112015029318A BR112015029318A2 BR 112015029318 A2 BR112015029318 A2 BR 112015029318A2 BR 112015029318 A BR112015029318 A BR 112015029318A BR 112015029318 A BR112015029318 A BR 112015029318A BR 112015029318 A2 BR112015029318 A2 BR 112015029318A2
Authority
BR
Brazil
Prior art keywords
bowel syndrome
irritable bowel
diagnosis
specific markers
pathway specific
Prior art date
Application number
BR112015029318A
Other languages
English (en)
Portuguese (pt)
Inventor
Selvaraj Fabiyola
Princen Fred
Singh Sharat
Westin Stefan
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112015029318A2 publication Critical patent/BR112015029318A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
BR112015029318A 2013-05-24 2014-05-22 marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável BR112015029318A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827506P 2013-05-24 2013-05-24
PCT/IB2014/061636 WO2014188378A1 (en) 2013-05-24 2014-05-22 Pathway specific markers for diagnosing irritable bowel syndrome

Publications (1)

Publication Number Publication Date
BR112015029318A2 true BR112015029318A2 (pt) 2017-07-25

Family

ID=50884973

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015029318A BR112015029318A2 (pt) 2013-05-24 2014-05-22 marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
BR112015029320A BR112015029320A8 (pt) 2013-05-24 2014-05-22 Ensaios específicos de vias para predição de diagnóstico de síndrome do intestino irritável

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112015029320A BR112015029320A8 (pt) 2013-05-24 2014-05-22 Ensaios específicos de vias para predição de diagnóstico de síndrome do intestino irritável

Country Status (14)

Country Link
US (5) US9891235B2 (https=)
EP (2) EP3004892B1 (https=)
JP (4) JP2016520199A (https=)
KR (2) KR20160010621A (https=)
CN (2) CN105579852B (https=)
AU (3) AU2014269961A1 (https=)
BR (2) BR112015029318A2 (https=)
CA (2) CA2913108A1 (https=)
HK (1) HK1223361A1 (https=)
IL (2) IL242595B (https=)
MX (1) MX367046B (https=)
RU (2) RU2015155552A (https=)
SG (2) SG11201509371XA (https=)
WO (2) WO2014188377A2 (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509371XA (en) * 2013-05-24 2015-12-30 Nestec Sa Pathway specific markers for diagnosing irritable bowel syndrome
AU2014284047B2 (en) 2013-06-21 2018-11-22 Ondek Pty Ltd Immunotherapy composition and use thereof
AU2015257589A1 (en) * 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
KR102546748B1 (ko) 2014-11-19 2023-06-22 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
CN107207559B (zh) 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
SG11201703729RA (en) 2014-11-19 2017-06-29 Nestec Sa Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
KR102527821B1 (ko) 2014-11-19 2023-05-02 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
CA2969326A1 (en) * 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
CN105987995A (zh) * 2015-02-04 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgG类抗体的酶联免疫试剂盒
CN105987996A (zh) * 2015-02-09 2016-10-05 东莞博捷生物科技有限公司 一种检测人抗酿酒酵母IgA类抗体的酶联免疫试剂盒
CN105061305A (zh) * 2015-08-31 2015-11-18 河南师范大学 一步合成3-甲基-2-吡啶甲酸甲酯的方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106399344B (zh) * 2016-06-01 2021-01-01 上海领潮生物新材料有限公司 一种vin-cdtb融合蛋白的制备方法
WO2018011691A1 (en) * 2016-07-12 2018-01-18 Nestec S.A. Competitive immunoassay methods
CN106188191A (zh) * 2016-07-13 2016-12-07 西安电子科技大学 基于gsh响应的诊治一体化有机分子探针及其制备方法
CA3036702A1 (en) * 2016-09-15 2018-03-22 Sun Genomics Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
US10428370B2 (en) 2016-09-15 2019-10-01 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554346B1 (en) 2016-12-14 2024-01-31 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2018112232A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
BR112019012071A2 (pt) 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de integrina
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3554342B1 (en) 2016-12-14 2024-07-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2018112256A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
EP3554485B9 (en) 2016-12-14 2023-09-27 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
US11134889B2 (en) 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
CA3046019A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
AU2018244922A1 (en) 2017-03-30 2019-09-12 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
EP3600414A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3600249A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
US12582809B2 (en) 2018-01-26 2026-03-24 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
ES3056147T3 (en) * 2018-02-09 2026-02-18 Metabolomic Diagnostics Ltd A system and method of generating a model to detect, or predict the risk of, an outcome
WO2019181830A1 (ja) * 2018-03-19 2019-09-26 富士フイルム和光純薬株式会社 精神疾患の判定方法
US12461111B2 (en) * 2018-04-24 2025-11-04 Universiteit Gent Intestinal and fecal biomarkers for intestinal health of poultry
AU2019278927A1 (en) 2018-06-01 2020-12-24 Bt Bidco, Inc. Devices and systems for gastrointestinal microbiome detection and manipulation
KR20210018823A (ko) * 2018-06-07 2021-02-18 4디 파마 피엘씨 Ibs 환자 계층화 방법
CN110607335B (zh) * 2018-06-14 2021-08-03 中国科学院微生物研究所 一种烟酰胺腺嘌呤二核苷酸类化合物生物合成方法
CN109324132A (zh) * 2018-10-31 2019-02-12 杭州佰辰医学检验所有限公司 高通量检测色氨酸及其代谢产物的试剂盒及其应用
US11488699B1 (en) 2018-12-09 2022-11-01 Cerner Innovation, Inc. Microbiota activity sensor and decision support tool
US11842795B1 (en) * 2018-12-17 2023-12-12 Cerner Innovation, Inc. Irritable bowel syndrome diagnostic sensor and decision support tool
FR3094492A1 (fr) * 2019-04-01 2020-10-02 Polyneuros Procédé de détection ou de suivi de l’évolution d’une maladie chronique dégénérative par dosage immunologique
CN114127317A (zh) * 2019-04-03 2022-03-01 4D制药科克有限公司 诊断疾病的方法
WO2020213732A1 (ja) * 2019-04-18 2020-10-22 株式会社サイキンソー 過敏性腸症候群の検査方法
US11884958B2 (en) * 2019-04-30 2024-01-30 Mayo Foundation For Medical Education And Research Assessing and treating functional gastrointestinal disorders
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
WO2020232262A1 (en) * 2019-05-16 2020-11-19 Procisedx Inc. Assay detection methods for vcam-1 and calprotectin
CN111351870A (zh) * 2019-12-03 2020-06-30 康美华大基因技术有限公司 一种肠易激综合征血清代谢标记物组合及其诊断试剂盒
US20230074127A1 (en) 2020-01-27 2023-03-09 Immundiagnostik Ag Test and in vitro diagnosis of irritable bowel syndrome
WO2021152586A1 (en) * 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Methods of analyzing microbiome, immunoglobulin profile and physiological state
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
KR102478205B1 (ko) * 2020-09-24 2022-12-15 경희대학교 산학협력단 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법
CN114755313B (zh) * 2021-01-08 2024-08-30 复旦大学附属华山医院 包含尿液nad+代谢物的急性肾损伤标志物
CN115724779B (zh) * 2021-09-01 2024-03-29 四川大学 酰胺烷二硫化合物、其制备方法和用途
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
WO2023180899A1 (en) * 2022-03-21 2023-09-28 Swain Manish Kumar Device and method for detecting diarrhea
CN116381222A (zh) * 2023-03-23 2023-07-04 北京巴瑞医疗器械有限公司 一种血清素发光免疫检测方法及血清素检测试剂盒
CN116990498B (zh) * 2023-09-28 2024-08-09 山东大学齐鲁医院 血浆色氨酸代谢物在儿童偏头痛诊断中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6218129B1 (en) * 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
AU784812B2 (en) * 1999-12-15 2006-06-29 Merck Sharp & Dohme Corp. Lipopeptides as antibacterial agents
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
CA2549971A1 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
WO2006012472A1 (en) 2004-07-21 2006-02-02 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20100094560A1 (en) 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8278057B2 (en) 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
CA2758531C (en) 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
US20120171672A1 (en) 2009-04-14 2012-07-05 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
WO2010151699A1 (en) 2009-06-25 2010-12-29 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
PH12012500850A1 (en) * 2009-10-30 2013-01-07 Prometheus Laboratories Inc Methods for diagnosing irritable bowel syndrome
BR112012012513A2 (pt) * 2009-11-25 2017-01-10 Prometheus Lab Inc método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo
US8445215B1 (en) * 2010-07-23 2013-05-21 Nestec S.A. Assays and methods for the detection of Crohn's disease
EP2710383B1 (en) * 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
SG11201401536QA (en) * 2011-10-21 2014-05-29 Nestec Sa Methods for improving inflammatory bowel disease diagnosis
CA2886991A1 (en) * 2012-10-05 2014-04-10 Nestec S.A. Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
SG11201509371XA (en) * 2013-05-24 2015-12-30 Nestec Sa Pathway specific markers for diagnosing irritable bowel syndrome
TWI853985B (zh) * 2013-12-04 2024-09-01 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫

Also Published As

Publication number Publication date
CN105392780A (zh) 2016-03-09
KR20160010621A (ko) 2016-01-27
JP2019151637A (ja) 2019-09-12
BR112015029320A8 (pt) 2023-01-03
US20160139148A1 (en) 2016-05-19
US20180321259A1 (en) 2018-11-08
AU2014269960A1 (en) 2015-11-26
US20170307637A1 (en) 2017-10-26
US9739786B2 (en) 2017-08-22
HK1223416A1 (en) 2017-07-28
AU2018214104A1 (en) 2018-08-30
JP2016520199A (ja) 2016-07-11
US20180136233A1 (en) 2018-05-17
IL242595B (en) 2019-01-31
US9891235B2 (en) 2018-02-13
KR20160013163A (ko) 2016-02-03
JP2016521683A (ja) 2016-07-25
WO2014188378A1 (en) 2014-11-27
CN105579852A (zh) 2016-05-11
IL242597B (en) 2019-02-28
WO2014188377A3 (en) 2015-03-05
US10036759B2 (en) 2018-07-31
MX367046B (es) 2019-08-02
HK1223361A1 (zh) 2017-07-28
RU2015155590A (ru) 2017-06-29
US20160130279A1 (en) 2016-05-12
RU2015155552A (ru) 2017-06-27
EP3004068A2 (en) 2016-04-13
SG11201509371XA (en) 2015-12-30
CA2912993A1 (en) 2014-11-27
EP3004892B1 (en) 2018-10-10
CA2913108A1 (en) 2014-11-27
US10338083B2 (en) 2019-07-02
SG11201509370UA (en) 2015-12-30
CN105579852B (zh) 2017-12-01
AU2014269960B2 (en) 2018-05-10
AU2014269961A1 (en) 2015-11-26
BR112015029320A2 (pt) 2017-07-25
WO2014188377A2 (en) 2014-11-27
EP3004892A1 (en) 2016-04-13
JP2019194600A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
EA201590027A1 (ru) Способы детекции заболеваний или состояний
CA2941917C (en) Methods for the diagnosis and treatment of inflammatory bowel disease
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
EP2946211A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF NURSE LUNGION AND NIERIN INSUFFICIENCY
MX2015015532A (es) Metodo y sistema de identificacion de biomarcadores.
LT3198033T (lt) Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
BR112014025189A2 (pt) prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica
BR112016002668A2 (pt) métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares
WO2013153461A3 (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
EP2967060A4 (en) METHOD FOR THE DIAGNOSIS, SELECTION AND TREATMENT OF ILLNESSES AND CONDITIONS BY OR IN CONNECTION WITH METHANOGENS
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
EP2914580A4 (en) THIOARYL DERIVATIVES AS GPR120 AGONISTS
MX2019002818A (es) Metodos para detectar anticuerpos neutralizantes anti-leptina.
EP2792752A4 (en) METHODS OF DIAGNOSIS AND / OR FORECASTING AKUTER KIDNEY DAMAGE
WO2014169011A3 (en) Methods for treating immune diseases

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]